• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, August 19, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Molecular imaging improves staging and treatment of pancreatic ductal adenocarcinomas

Bioengineer by Bioengineer
July 7, 2021
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Image created by M Röhrich, University Hospital Heidelberg, Germany.

Reston, VA–For patients with pancreatic ductal adenocarcinomas (PDAC), molecular imaging can improve staging and clinical management of the disease, according to research published in the June issue of The Journal of Nuclear Medicine. In a retrospective study of PDAC patients, the addition of PET/CT imaging with 68Ga-FAPI led to restaging of disease in more than half of the patients, most notably in those with local recurrence.

PDAC is a highly lethal cancer, with a five-year survival rate of less than 10 percent. Optimal imaging of PDAC is crucial for accurate initial TNM (tumor, node, metastases) staging and selection of the primary treatment. Follow-up imaging is also important to accurately detect local recurrence or metastatic spread as early and as completely as possible.

“Currently, contrast-enhanced CT is the gold standard when it comes to TNM staging, and PET imaging isn’t typically part of the clinical routine” stated Manuel Röhrich, MD, nuclear medicine physician at Heidelberg University Hospital in Heidelberg, Germany. “However, we know that PDAC is composed of certain fibroblasts that express fibroblast activation protein, which can be imaged with the novel PET radiotracer 68Ga-FAPI. Given this characteristic, we sought to explore the utility of 68Ga-FAPI PET/CT to image FDAC patients.”

The study included 19 FDAC patients who received contrast-enhanced CT imaging followed by 68Ga-FAPI PET/CT. Results from the 68Ga-FAPI PET/CT scans were then compared with TNM staging based on contrast-enhanced CT. Changes in oncological management were recorded.

68Ga-FAPI PET/CT-based TNM staging differed from contrast-enhanced CT imaging in 10 out of 19 patients, which resulted in changes in TNM staging. Of the 12 patients with recurrent disease, eight were upstaged, one was downstaged and three remained the same. In the seven patients newly diagnosed with PDAC, one was upstaged, while the staging remained the same for six of the patients.

“This analysis suggests that 68Ga-FAPI PET/CT is a promising new imaging modality in staging of PDAC that may help to detect new or clarify inconclusive results obtained by standard CT imaging,” said Röhrich. He added, “Improvement in survival can only be achieved by effective treatment approaches customized to the individual patient’s disease status. Thus, hybrid imaging using FAPI tracer may open up new applications in staging and restaging of PDAC.”

###

The authors of “Impact of 68Ga-FAPI-PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas” include Manuel Röhrich, Fabian Staudinger, Dawn, P. Liew, Clemens Kratochwil and Hendrik Rathke, Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany; Patrick Naumann, Jakob Liermann, Klaus Herfarth and Stefan A. Koerber, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, National Center for Tumor diseases (NCT), Heidelberg, Germany, and Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany; Frederik L. Giesel, Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany, and German Cancer Consortium (DKTK), partner site Heidelberg, Germany; Peter L. Choyke, Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Annika Wefers, Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany, and Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; Dirk Jäger, Department of Medical Oncology and Internal Medicine Virgin Islands, National Center for Tumor Diseases, University Hospital Heidelberg, Germany, and Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany; Jürgen Debus, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, National Center for Tumor diseases (NCT), Heidelberg, Germany, and Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany, German Cancer Consortium (DKTK), Partner Site Heidelberg, Germany, Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, and Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Uwe Haberkorn, Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany, and German Cancer Consortium (DKTK), Partner Site Heidelberg, Germany, Clinical Cooperation Unit, Department of Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany, and Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research DZL, Heidelberg, Germany; and Matthias Lang, Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany, and Department of Surgery, Heidelberg University Hospital, Heidelberg, Germany, Member of the German Center for Lung Research DZL, Heidelberg, Germany.

This work was funded by the Federal Ministry of Education and Research, grant number 13N 13341. Uwe Haberkorn, Clemens Kratochwil and Frederik Giesel have filed a patent application for quinoline-based FAP-targeting agents for imaging and therapy in nuclear medicine. This retrospective study was approved by the local institutional review board (study number S115/2020).

Visit JNM‘s new website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed.

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or [email protected]

About JNM and the Society of Nuclear Medicine and Molecular Imaging

The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 11 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging–precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit http://www.snmmi.org.

Media Contact
Rebecca Maxey
[email protected]

Original Source

http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=37239

Related Journal Article

http://dx.doi.org/10.2967/jnumed.120.253062

Tags: cancerDiagnosticsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

The large-scale clinical study identified the long-term rebleeding rates and predictive rebleeding factors

Obscure gastrointestinal bleeding: rebleeding rates and rebleeding predictors found

August 19, 2022
Scientists have developed improved methods for generating micro-organospheres (MOS) and have shown that they can be used as patient avatars for studies involving direct viral infection, immune cell penetration and high-throughput therapeutic drug screening - something that is not obtainable with conventional patient-derived models.

Next generation patient avatars: Expanding the possibilities with MicroOrganospheres

August 18, 2022

First in nation: UC San Diego health offers treatment for hereditary amyloidosis

August 18, 2022

Machine learning model predicts fall risk for lower limb amputees with up to 80% accuracy, with implications for future smartphone apps

August 18, 2022
Please login to join discussion

POPULAR NEWS

  • Picture of the horse specimen.

    Ancient DNA clarifies the early history of American colonial horses

    57 shares
    Share 23 Tweet 14
  • Fatigue, headache among top lingering symptoms months after COVID

    40 shares
    Share 16 Tweet 10
  • Chi-Huey Wong awarded Tetrahedron Prize for Creativity in Organic Synthesis

    38 shares
    Share 15 Tweet 10
  • Dogs lying in the middle of the road after sunrise at Kewa Pueblo, in no hurry to start the day

    34 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

VaccinesUniversity of WashingtonUrogenital SystemVirologyVehiclesWeather/StormsWeaponryViolence/CriminalsVirusVaccineZoology/Veterinary ScienceUrbanization

Recent Posts

  • Early blood tests predict death, severe disability for traumatic brain injury
  • Obscure gastrointestinal bleeding: rebleeding rates and rebleeding predictors found
  • Collaborations inspired early-career NIH grant that could lead to treatment breakthroughs for a range of medical conditions
  • Novel hypotheses that answer key questions about the evolution of sexual reproduction
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In